Sebastian Fucile

TL;DR: Patients and primary care physicians should consider a cumulative SCS dose of 1 g per year as a highly relevant and easy-to-recall threshold and strategies to improve asthma control and reduce inappropriate use of systemic corticosteroids are needed.

TL;DR: Non-inferiority of either dose of IND/GLY/MF to SAL/FLU high dose + TIO in terms of Asthma Quality of Life Questionnaire (AQLQ) was confirmed, indicating improved lung function, asthma control and health status versus SAL/FlU highdose +-TIO, whileIND/GLy/MF medium-dose had comparable efficacy but at a corresponding lower steroid dose.

TL;DR: The utility of the CID endpoint as a means of monitoring COPD worsening in patients with moderate-to-severe COPD is confirmed, providing further evidence for the benefit of dual bronchodilation in this patient population.

TL;DR: The benefits observed with IND/GLY confirm dual bronchodilator as the preferred therapy in patients with moderate-to-very-severe COPD regardless of sex and provide superior efficacy to monotherapy or SFC in both men and women.

TL;DR: Although there were gender differences in baseline characteristics, IND/GLY demonstrated similar trends for exacerbation prevention and lung function improvement in men and women with moderate-to-very-severe COPD and a history of exacerbations compared with SFC.